ArticleThe oncologist2025
Immuno-OncologyThe adverse event of interstitial lung disease in patients treated with antibody-drug conjugates.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis.Translational lung cancer research · 2026Review
- Pulmonary Complications of Cancer Therapy: Clinical Presentations, Imaging Patterns, and Management Strategies.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThere has been a yearly increase in the incidence of interstitial lung disease (ILD) adverse events associated with antibody-drug conjugates (ADCs), which is becoming a significant challenge for the clinical application of ADCs. We aim to conduct an exhaustive analysis of the clinical characteristics and outcomes of ADC-associated ILD in the real world.
methodsWe utilized the FDA Adverse Event Reporting System database spanning from January 2004 to September 2023 to evaluate the clinical characteristics, onset times, and outcomes of ADC-associated ILD adverse events in patients. Additionally, safety signals were generated using disproportionality and Bayesian analyses to evaluate the association between ADC and ILD.
resultsOut of the fifteen ADCs, ten were recorded to have caused ILD adverse events, accounting for a total of 643 reported cases. Eight ADCs exhibited statistically significant safety signals related to ILD in both disproportionality and Bayesian analyses. Trastuzumab deruxtecan recorded the highest reporting odds ratio (ROR) = 49.04 [95% confidence interval (CI) =44.41-54.17], proportional reporting ratio (PRR) = 43.90 (χ2 = 18 297.87), empirical Bayes geometric mean = 43.45 (95% one-sided CI, 39.98). 44.20% of adverse reactions were recognized within the first month of ADC treatment. The median time to onset for ILD related to gemtuzumab ozogamicin was notably the shortest at 4 days [interquartile range (IQR): 2-12 days], and it had the highest fatality proportion, standing at 57.14%.
conclusionsThis study analyzed demographic, temporal and outcome profiles of ADC-related ILD cases and identified high-risk signals. These findings help raise awareness and improve the monitoring of adverse events related to ADC. In the future, large-scale prospective studies are needed to further confirm and explore the underlying biological mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.